返回 
加入收藏
《药品质量抽查检验管理办法》与《药品质量抽查检验管理规定》中检验和复验内容的对比分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 《药品质量抽查检验管理办法》与《药品质量抽查检验管理规定》中检验和复验内容的对比分析 |
| TITLE： | Comparative Analysis of Test and Retest Contents between the Management of Drug Quality Sampling and Testing and the Regulation of Drug Quality Sampling and Testing |
| 摘要： | 目的：为药品抽检工作相关人员理解并执行《药品质量抽查检验管理办法》中的新要求提供参考。方法：对比《药品质量抽查检验管理办法》和《药品质量抽查检验管理规定》中对检验和复验工作的要求，分析修订或新增内容并提出实施建议。结果与结论：针对药品监管需要，在《药品质量抽查检验管理规定》的基础上，《药品质量抽查检验管理办法》对检验和复验工作的相关要求进行了修订和补充。在对检验工作的要求中，该办法修订了检验项目要求，明确了检验时限要求，新增了检验报告、原始记录、质量管理体系要求以及“严重风险”的定义及报告要求，对检验机构提出了开展探索性研究的要求，并新增了检验机构和检验人员行为要求。在对复验工作的要求中，该办法修订了申请复验应提交的资料，增加了经办人身份证明、时限证明，修订了不得复验的情况，增加了检出为明显可见异物时的处理方式，并新增了复验报告传递要求。建议药品检验工作的相关人员关注上述变更内容，加强检验能力建设，加强检验时间和检验质量管理，重视严重质量风险，积极开展探索性研究，并加强对自身检验行为的规范；严格审核复验资料，重视新修订的不得复验的情形，并应按要求和实际情况全面传递复验报告，积极执行并落实《药品质量抽验管理办法》。 |
| ABSTRACT： | OBJECTIVE：To provide re ference for the relevant personnel of drug quality sampling and testing to understand and implement the new requirements in the Management of Drug Quality Sampling and Testing . METHODS ：The test and retest requirements were compared between the Management of Drug Quality Sampling and Testing and the Regulation of Drug Quality Sampling and Testing. The revised and newly added contents were analyzed ，and the recommendations for implementation were put forward. RESULTS & CONCLUSIONS ：Referring to drug regulation need ，related requirements of test and retest in the Management of Drug Quality Sampling and Testing were modified and supplemented on the basis of the Regulation of Drug Quality Sampling and Testing . In the requirements for test ，the requirements for test items were revised ，the requirements for test time limit were confirmed ，the requirements for test report ，original record and quality management system ，the definition of “serious risk ” and its reporting requirements were added newly. The requirements for exploratory research were put forward for test institutions， as well as new requirements for test institutions and inspectors ’behaviors. In the requirements for retest ，the materials to be submitted for retest were revised ，and the identity certificate of the manager and time limit certificate were added ；the situation of no-retest were revised ，and the treatment method were added when obviously visible foreign matters were detected ；transfer requirements for retest report were added newly. It is suggested that the relevant personnel should pay more attention to the above changes，strengthen the construction of test capacity a nd the management of tes t time and quality ，attach importance to serious quality risks ，actively carry out exploratory research ，and mind their own test behaviors ；strictly review retest materials ， pay attention to the newly revised no-test and comprehensively transfer the retest report according to the requir ements and actual situation ，conduct and implement the Management of Drug Quality Sampling and Testing actively. |
| 期刊： | 2020年第31卷第14期 |
| 作者： | 刘文，朱炯，胡骏，王翀，胡增峣 |
| AUTHORS： | LIU Wen，ZHU Jiong，HU Jun，WANG Chong ，HU Zengyao |
| 关键字： | 药品质量抽检管理；检验；复验；对比分析 |
| KEYWORDS： | Management of drug quality sampling and testing；Test；Retest；Comparative analysis |
| 阅读数： | 606 次 |
| 本月下载数： | 7 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
